Protagonist Therapeutics, Inc. (PTGX) - 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated May 5, 2026, reports the financial results for Protagonist Therapeutics, Inc. for the quarter ended March 31, 2026. The company is an emerging growth company incorporated in Delaware and trades on The Nasdaq Stock Market LLC under the symbol PTGX.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that these results were reported via a press release (Exhibit 99.1) rather than containing the detailed financial data within the 8-K body itself.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. Investors must refer to the incorporated press release for comparative analysis.
Guidance, Outlook, and Risks
The filing references a corporate update included in the press release but does not contain specific guidance, outlook, management commentary, risks, contingencies, or unusual items within the text of this 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2026 financial figures and cash runway.
- Verify the company's status as an emerging growth company and any election regarding extended transition periods for accounting standards.
- Confirm the date of the earliest event reported (May 5, 2026) against market trading activity.
- Check for any subsequent filings that may incorporate the press release by reference, as this 8-K explicitly states the information is not deemed "filed" for Section 18 liability purposes.